Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patientsâ lives. Aptevo has a commercial product, IXINITYÂŽ coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology â the ADAPTIR⢠modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source
No articles found.
Catalyst is focused on developing novel medicines to address serious medical condi...
Catalyst is focused on developing novel medicin...
DBV Technologies is developing ViaskinÂŽ, an investigational proprietary technolog...
DBV Technologies is developing ViaskinÂŽ, an in...
PolarityTE is a commercial-stage biotechnology and regenerative biomaterials compa...
PolarityTE is a commercial-stage biotechnology ...
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with ...
Co-Diagnostics, Inc., a Utah corporation, is a ...
Celcuity is a cellular analysis company that is discovering new cancer sub-types a...
Celcuity is a cellular analysis company that is...
HJLI specializes in developing and manufacturing bioprosthetic medical devices to ...
HJLI specializes in developing and manufacturin...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...
Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...
Compugen is a drug discovery company with a unique, broadly applicable, predictive...
Compugen is a drug discovery company with a uni...
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...
Harpoon Therapeutics is a clinical-stage immuno...
Epizyme, Inc. is a clinical stage biopharmaceutical company creating novel epigene...
Epizyme, Inc. is a clinical stage biopharmaceut...
Join the National Investor Network and get the latest information with your interests in mind.